Dr. Clark is responsible for monitoring the formulation development and preclinical testing of pipeline products for Product Development at CONRAD. The scope of projects she helps oversee includes the development of intravaginal rings and combination gels, and the in vivo and in vitro evaluation of pharmacokinetics and safety for these and other pipeline products. Dr. Clark received her B.S. in Neurobiology, Physiology and Behavior from the University of California, Davis in 2001 and her Ph.D. in Bioengineering from the University of Utah in 2008. She has been an active researcher in the microbicides field for several years, beginning with her dissertation work on the development of in situ gelling formulations for enhanced microbicide gel deployment and retention. Dr. Clark joined CONRAD in 2009 as Manager, Drug Delivery. She is also an Assistant Professor in the Department of Obstetrics and Gynecology at Eastern Virginia Medical School.
- Engineering a segmented dual-reservoir polyurethane intravaginal ring for simultaneous prevention of HIV transmission and unwanted pregnancy.
- Pharmacokinetic and safety analyses of tenofovir and tenofovir/emtricitabine vaginal tablets in pigtailed macaques.
- Multipurpose prevention technologies: Products in development.
- Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies.
- Multipurpose prevention technologies: Products in development
- Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies
- Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring
- Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet containing a single excipient
- A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis
- Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits
- Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir
- Development of a UC781 releasing polyethylene vinyl acetate vaginal ring
- An intravaginal ring for the simultaneous delivery of multiple drugs
- Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model
- Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings
- Design of tenofovir-UC781 combination microbicide vaginal gels
- Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring
- A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781
- Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies
- Enzymatic triggered release of an HIV-1 entry inhibitor from prostate specific antigen degradable microparticles
- Ethylene vinyl acetate intravaginal rings for the simultaneous delivery of the antiretroviral UC781 and contraceptive levonorgestrel
- Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices
- Preclinical evaluation of UC781 microbicide vaginal drug delivery
- Recent Trends in Microbicide Formulations
- Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers
- Design of a semisolid vaginal microbicide gel by relating composition to properties and performance
- Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles